Examkin

Soru

Zorluk: OrtaMonitoring and Treatment Evaluation

A 6262-year-old woman is admitted to the hospital with a newly diagnosed acute deep vein thrombosis of the right lower extremity. Her past medical history is significant for active gastric adenocarcinoma and chronic kidney disease stage 4, with a recent baseline creatinine clearance of 24 mL/min24\text{ mL/min}. The clinical team decides to initiate dose-adjusted subcutaneous enoxaparin for therapeutic anticoagulation. Given the patient's comorbidities and pharmacotherapy, which of the following are appropriate monitoring and management strategies? (Select all that apply)

  1. Measurement of peak anti-factor Xa levels 44 hours after the enoxaparin doseCevap
  2. Regular assessment of platelet count between days 44 and 1414 of therapyCevap
  3. C
    Titration of the enoxaparin dose to maintain an activated partial thromboplastin time of 1.51.5 to 2.52.5 times the normal baseline
  4. D
    Immediate discontinuation of enoxaparin if the platelet count drops by 15%15\% within the first 4848 hours of treatment
  5. E
    Preemptive dose reduction of enoxaparin if a cytochrome P450 inhibitor, such as amiodarone, is concomitantly initiated

Cevap

The appropriate strategies are measuring peak anti-factor Xa levels 4 hours post-dose and regularly monitoring the platelet count between days 4 and 14.
Enoxaparin is a low-molecular-weight heparin (LMWH) that is primarily cleared by the kidneys. In patients with severe renal impairment (creatinine clearance <30 mL/min< 30\text{ mL/min}), the drug can accumulate and cause severe hemorrhage. Therefore, standard dosing is contraindicated; if used, the dose must be adjusted and closely monitored using peak anti-factor Xa levels drawn 44 hours after the subcutaneous injection. Additionally, any patient receiving a heparin product requires surveillance for heparin-induced thrombocytopenia (HIT). Immune-mediated Type 2 HIT classically occurs 55 to 1010 days after initiation, making routine platelet count checks between days 44 and 1414 a mandatory monitoring parameter.

Adım Adım Çözüm

1
Identify the high-risk pharmacotherapy and relevant patient comorbidities.
The patient is starting enoxaparin (a low-molecular-weight heparin) and has severe chronic kidney disease (creatinine clearance <30 mL/min< 30\text{ mL/min}).
Comorbidities alter the pharmacokinetics and monitoring requirements of anticoagulants.
2
Determine the necessary pharmacokinetic monitoring for the drug in this specific clinical context.
Because enoxaparin is renally cleared, its dose must be reduced in severe renal impairment, and therapeutic efficacy/safety is monitored via peak anti-factor Xa levels drawn 44 hours post-dose.
Standard weight-based dosing without monitoring in severe renal disease leads to drug accumulation and high bleeding risk.
3
Identify class-wide adverse effect monitoring requirements.
All heparin products require monitoring for heparin-induced thrombocytopenia (HIT). The highest risk period for immune-mediated HIT (Type 2) is days 55 to 1010, necessitating platelet count checks between days 44 and 1414.
Type 2 HIT is a limb- and life-threatening prothrombotic complication.

Anahtar Kavram

Patients with severe renal impairment (CrCl <30 mL/min< 30\text{ mL/min}) receiving therapeutic enoxaparin require anti-factor Xa level monitoring. All patients on heparin products require platelet monitoring for HIT.
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru